Irvine, United States
Immunis, Inc., founded in 2019, is a United States-based, clinical-stage biotechnology company pioneering the development of stem cell-derived biologics to combat age-related diseases and immune dysfunction. Their innovative approach targets the secretome—a collection of cell-secreted factors that have the potential to reshape immune responses. This makes it a compelling therapeutic avenue for autoimmune, neurodegenerative, and age-related muscle wasting diseases, such as sarcopenia.
The company's flagship product, IMM01-STEM, has shown significant promise in pre-clinical studies by enhancing muscle regeneration, mass, and functionality, as published in respected journals like GeroScience. Given that 100% of humans develop sarcopenia with age, the unmet medical need for such solutions is substantial. Their first clinical trial focused on evaluating this product's safety in elderly patients.
In its pursuit to address sarcopenic obesity—a condition exacerbated by increasing global obesity rates—Immunis recently received a $15.79M Venture Round investment on July 1, 2024. This capital is crucial for advancing their ongoing Phase 2 clinical trials. As an investment opportunity, Immunis, Inc. offers a novel approach that appeals to investors seeking high-impact solutions targeting a growing medical concern.
